Total Payments
$252,698
2024 Payments
$32,707
Companies
20
Transactions
498
Medicare Patients
726
Medicare Billing
$75,289
Payment Breakdown by Category
Consulting$179,656 (71.1%)
Other$28,134 (11.1%)
Travel$22,749 (9.0%)
Food & Beverage$12,494 (4.9%)
Research$9,663 (3.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $179,656 | 64 | 71.1% |
| Travel and Lodging | $22,749 | 61 | 9.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $17,934 | 12 | 7.1% |
| Food and Beverage | $12,494 | 341 | 4.9% |
| Unspecified | $9,663 | 16 | 3.8% |
| Honoraria | $5,300 | 3 | 2.1% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $4,900 | 1 | 1.9% |
Payments by Type
General
$243,034
482 transactions
Research
$9,663
16 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Biotech, Inc. | $70,369 | 241 | $0 (2024) |
| PFIZER INC. | $36,539 | 29 | $0 (2024) |
| Eli Lilly and Company | $26,616 | 53 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $25,595 | 12 | $0 (2023) |
| ABBVIE INC. | $17,575 | 71 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $14,333 | 28 | $0 (2024) |
| UCB, Inc. | $13,851 | 10 | $0 (2022) |
| Janssen Scientific Affairs, LLC | $11,017 | 7 | $0 (2021) |
| Lilly USA, LLC | $9,714 | 4 | $0 (2024) |
| Celgene Corporation | $8,692 | 19 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $32,707 | 75 | Janssen Biotech, Inc. ($20,722) |
| 2023 | $23,531 | 43 | Janssen Biotech, Inc. ($6,747) |
| 2022 | $37,452 | 45 | E.R. Squibb & Sons, L.L.C. ($16,569) |
| 2021 | $32,100 | 28 | Janssen Scientific Affairs, LLC ($10,900) |
| 2020 | $27,048 | 28 | Eli Lilly and Company ($10,238) |
| 2019 | $42,769 | 105 | UCB, Inc. ($11,131) |
| 2018 | $15,454 | 82 | Janssen Biotech, Inc. ($8,612) |
| 2017 | $41,637 | 92 | PFIZER INC. ($11,181) |
All Payment Transactions
498 individual payment records from CMS Open Payments — Page 1 of 20
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/21/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Consulting Fee | Cash or cash equivalent | $2,125.00 | General |
| Category: Immunology | ||||||
| 12/07/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Travel and Lodging | In-kind items and services | $856.21 | General |
| Category: Immunology | ||||||
| 12/07/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Travel and Lodging | In-kind items and services | $417.38 | General |
| Category: Immunology | ||||||
| 12/07/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Travel and Lodging | In-kind items and services | $413.15 | General |
| Category: Immunology | ||||||
| 12/07/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $38.42 | General |
| Category: Immunology | ||||||
| 11/19/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $17.98 | General |
| Category: Immunology | ||||||
| 11/18/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $10.57 | General |
| Category: Immunology | ||||||
| 11/14/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $18.40 | General |
| Category: Immunology | ||||||
| 11/11/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $33.70 | General |
| Category: Immunology | ||||||
| 11/07/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $19.24 | General |
| Category: INTERNAL MEDICINE | ||||||
| 11/04/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $10.57 | General |
| Category: Immunology | ||||||
| 10/28/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $70.37 | General |
| Category: IMMUNOLOGY | ||||||
| 10/28/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $19.00 | General |
| Category: IMMUNOLOGY | ||||||
| 10/24/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $14.70 | General |
| Category: Immunology | ||||||
| 10/23/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $16.77 | General |
| Category: Immunology | ||||||
| 10/22/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $42.44 | General |
| Category: Immunology | ||||||
| 10/18/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $9.00 | General |
| Category: Immunology | ||||||
| 10/07/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $11.48 | General |
| Category: Immunology | ||||||
| 09/30/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $23.03 | General |
| Category: Immunology | ||||||
| 09/30/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $10.81 | General |
| Category: Immunology | ||||||
| 09/26/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $29.51 | General |
| Category: INTERNAL MEDICINE | ||||||
| 09/25/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Food and Beverage | In-kind items and services | $150.00 | General |
| Category: Immunology | ||||||
| 09/25/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $13.27 | General |
| Category: Immunology | ||||||
| 08/06/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $71.51 | General |
| Category: IMMUNOLOGY | ||||||
| 07/18/2024 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $24.85 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| TOFACITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $5,250 | 4 |
| Effects of Transient and Persistent Anti-Drug Antibodies to Certolizumab Pegol: Longitudinal Data from a 7 Year Study in Crohn's Disease | UCB, Inc. | $2,300 | 1 |
| TOFACITINIB IBD CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $780.00 | 1 |
| A Non-Interventional, Long term, Post-Marketing Registry of Patients Treated with Certolizumab Pegol (CIMZIA) For Crohns Disease | UCB, Inc. | $420.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 151 | 173 | $79,600 | $19,180 |
| 2022 | 6 | 150 | 167 | $59,457 | $15,018 |
| 2021 | 7 | 213 | 234 | $79,121 | $21,037 |
| 2020 | 9 | 212 | 231 | $83,068 | $20,054 |
Total Patients
726
Total Services
805
Medicare Billing
$75,289
Procedure Codes
27
All Medicare Procedures & Services
27 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 49 | 64 | $25,053 | $7,536 | 30.1% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 48 | 48 | $30,312 | $5,599 | 18.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 30 | 37 | $9,525 | $2,704 | 28.4% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 12 | 12 | $9,529 | $2,609 | 27.4% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 12 | 12 | $5,181 | $731.29 | 14.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 38 | 49 | $15,095 | $5,341 | 35.4% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 41 | 41 | $26,807 | $5,276 | 19.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 31 | 35 | $7,654 | $2,730 | 35.7% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 17 | 18 | $8,107 | $1,105 | 13.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 11 | 11 | $1,560 | $505.61 | 32.4% |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | Facility | 2022 | 12 | 13 | $233.90 | $59.62 | 25.5% |
| 45380 | Biopsy of the large bowel using an endoscope (colonoscopy) | Facility | 2021 | 54 | 57 | $36,125 | $7,752 | 21.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 42 | 50 | $15,120 | $5,719 | 37.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 42 | 49 | $10,491 | $3,727 | 35.5% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 22 | 23 | $10,029 | $1,706 | 17.0% |
| 43235 | Diagnostic examination of esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 13 | 13 | $5,042 | $1,236 | 24.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 11 | 13 | $1,810 | $759.85 | 42.0% |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | Facility | 2021 | 29 | 29 | $504.60 | $135.96 | 26.9% |
| 45380 | Biopsy of large bowel using an endoscope | Facility | 2020 | 42 | 46 | $29,531 | $5,590 | 18.9% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 37 | 44 | $12,323 | $3,981 | 32.3% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope | Facility | 2020 | 13 | 13 | $10,481 | $2,870 | 27.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 31 | 35 | $6,586 | $1,799 | 27.3% |
| 43235 | Diagnostic examination of esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2020 | 17 | 17 | $6,603 | $1,519 | 23.0% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 12 | 12 | $3,947 | $1,438 | 36.4% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2020 | 17 | 19 | $8,329 | $1,355 | 16.3% |
About Scott Lee
Scott Lee is a Gastroenterology healthcare provider based in Seattle, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1316022122.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Scott Lee has received a total of $252,698 in payments from pharmaceutical and medical device companies, with $32,707 received in 2024. These payments were reported across 498 transactions from 20 companies. The most common payment nature is "Consulting Fee" ($179,656).
As a Medicare-enrolled provider, Lee has provided services to 726 Medicare beneficiaries, totaling 805 services with total Medicare billing of $75,289. Data is available for 4 years (2020–2023), covering 27 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Seattle, WA
- Active Since 10/27/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1316022122
Products in Payments
- STELARA (Biological) $47,082
- XELJANZ (Drug) $28,114
- ZEPOSIA (Drug) $23,011
- TREMFYA (Drug) $20,285
- Cimzia (Drug) $14,231
- Entyvio (Biological) $14,181
- VELSIPITY (Drug) $7,845
- SIMPONI (Biological) $7,789
- Humira (Biological) $6,944
- REMICADE (Biological) $6,231
- UCERIS (Drug) $5,101
- RINVOQ (Biological) $4,228
- ZYMFENTRA (Biological) $2,901
- Mytesi (Drug) $1,562
- RENFLEXIS (Biological) $1,100
- HUMIRA (Biological) $1,043
- Inflectra (Biological) $800.00
- CIMZIA (Drug) $420.00
- SKYRIZI (Biological) $330.47
- Ozanimod (Drug) $180.81
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Seattle
Kris Kowdley, Md, MD
Gastroenterology — Payments: $1.4M
Gastroenterology $1.4M
Andrew Ross, Md, MD
Gastroenterology — Payments: $109,536
Gastroenterology $109,536
Dr. Anand Singla, M.d, M.D
Gastroenterology — Payments: $79,123
Gastroenterology $79,123
George Mcdonald
Gastroenterology — Payments: $69,477
Gastroenterology $69,477
Shayan Irani, Md, MD
Gastroenterology — Payments: $58,182
Gastroenterology $58,182
Dr. Adam Templeton, M.d, M.D
Gastroenterology — Payments: $58,097
Gastroenterology $58,097